Merit Medical announced on May 20 that it acquired Biolife Delaware in a merger transaction through which Biolife has become a wholly-owned subsidiary of Merit. The aggregate transaction consideration, paid in cash and assumption of Biolife liabilities, was approximately $120 million.
Headquartered in Sarasota, Florida, Biolife Delaware manufactures unique patented hemostatic devices under the brand names StatSeal and WoundSeal.
Merit Medical develops, manufactures and markets medical devices for interventional and diagnostic procedures worldwide. According to its FY 2024 earnings report, the company announced $1.35 billion in revenues during the full year of 2024.
This strategic acquisition positions Merit to provide clinicians with more products designed to standardize, simplify and minimize post-procedure care and maintenance.
According to data captured in the LevinPro HC database, this marks the 38th Medical Device transaction of 2025. There were 87 Medical Device acquisitions announced during 2024, 112 announced in 2023 and 124 announced during 2022.
